ReviewFrontiers in neurology2026
No-reflow in acute ischemic stroke: mechanisms, measurements, and molecular markers.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: No-reflow is a critical microvascular phenomenon in acute ischemic stroke in which patients fail to achieve adequate tissue reperfusion despite successful recanalization of a large vessel occlusion. It affects at least 25% of patients after reperfusion and results from persistent microvascular dysfunction that prevents restoration of normal blood flow to ischemic tissue, leading to ongoing injury. Objective: This paper synthesizes historical, mechanistic, diagnostic, and therapeutic perspectives on the no-reflow phenomenon to clarify its pathophysiology and highlight gaps limiting clinical translation. Methods: A narrative review was conducted using foundational experimental studies and contemporary clinical literature. Evidence was organized into mechanistic domains, measurement modalities, and therapeutic strategies, integrating molecular, imaging, and neurointerventional findings. Results: No-reflow arises from interacting mechanisms, including microvascular occlusions from embolic fragments, platelet aggregation, erythrocyte/fibrin deposition, and leukocyte plugging, where neutrophils can lodge within capillaries and impede flow. Vascular remodeling driven by endothelial dysfunction, oxidative stress, necroptosis, microglial activation, and pericyte constriction further compromises perfusion, while cytotoxic edema produces microvessel compression. Measurement remains inconsistent due to the absence of standardized diagnostic criteria, with current tools ranging from TICI-based angiographic assessments to perfusion imaging and molecular biomarkers. Emerging therapies target distal embolization, microvascular thrombosis, vasoconstriction, inflammation, and ischemic conditioning, while selective hypothermia shows promise in experimental models. Conclusion: No-reflow phenomenon is a multifactorial barrier to functional recovery after stroke, and its clinical impact is amplified by diagnostic ambiguity. Advancing real-time measurement tools and mechanism-based therapies is essential to improving outcomes after recanalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.